Gastrointestinal Diseases

Gastroenterology
3
Pipeline Programs
5
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 4 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
1 program
1
Bacillus clausiiPhase 41 trial
Active Trials
NCT00424905Completed60
Abbott
AbbottABBOTT PARK, IL
1 program
1
Peptide based enteral formulaPhase 3Peptide1 trial
Active Trials
NCT01191112Completed27Est. Nov 2011
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
Buscopan® plusPhase 21 trial
Active Trials
NCT02229786Completed1,637
Hamilton medical
Hamilton medicalSwitzerland - Bonaduz
1 program
Abdominal Drainage Fluid CollectionN/A1 trial
Active Trials
NCT06541431RecruitingEst. Jul 2025
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Symptoms and Endoscopic Results in Consideration of PretreatmentN/A1 trial
Active Trials
NCT00612404Completed16,255

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SanofiBacillus clausii
AbbottPeptide based enteral formula
Boehringer IngelheimBuscopan® plus
Hamilton medicalAbdominal Drainage Fluid Collection
AstraZenecaSymptoms and Endoscopic Results in Consideration of Pretreatment

Clinical Trials (5)

Total enrollment: 17,979 patients across 5 trials

NCT00424905SanofiBacillus clausii

DIAMANTE - Diseases Infectious Analysis Microflora Antibiotic Effect

Start: Dec 200660 patients
Phase 4Completed
NCT01191112AbbottPeptide based enteral formula

Evaluation of the Safe Use and Tolerance of a Peptide-based Formula in a Pediatric Population

Start: Jan 2011Est. completion: Nov 201127 patients
Phase 3Completed
NCT02229786Boehringer IngelheimBuscopan® plus

Efficacy and Tolerability of Buscopan Plus in Painful Gastric or Intestinal Spasms

Start: Feb 19981,637 patients
Phase 2Completed
NCT06541431Hamilton medicalAbdominal Drainage Fluid Collection

Analytical Validation of Stream™ Platform

Start: Nov 2024Est. completion: Jul 2025
N/ARecruiting
NCT00612404AstraZenecaSymptoms and Endoscopic Results in Consideration of Pretreatment

Symptoms and Endoscopic Results in Consideration of Pretreatment

Start: Sep 200516,255 patients
N/ACompleted

Related Jobs in Gastroenterology

Specialty Representative, Gastroenterology – Minneapolis, Minnesota

AbbVie
Remote
7h ago

Key Account Director, Diagnostics and Research

Tempus
Remote
20h ago
$150K - $200K/yr

Experienced Clin Programmer

Johnson & Johnson
High Wycombe, Buckinghamshire, United Kingdom
20h ago

[Innovative Medicine] Director, Government Affairs and Policy Dept., Integrated Market Access Div.

Johnson & Johnson
Chiyoda, Tokyo, Japan
20h ago

Analyst Accounting

Johnson & Johnson
Suzhou, Jiangsu, China
20h ago

Lead Product Security Engineer

Johnson & Johnson
Danvers, Massachusetts, United States of America
20h ago
$94K - $152K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 17,979 patients
5 companies competing in this space

Related Indications

Hepatic Impairment(79)Gastroesophageal Reflux Disease(37)Irritable Bowel Syndrome(29)Gastroesophageal Reflux(27)Liver Transplantation(24)Celiac Disease(23)Hepatic Insufficiency(22)Liver Cirrhosis(22)Gastroesophageal Reflux Disease (GERD)(14)Hepatic Encephalopathy(12)